Staff who provide data to the vaccine panel have been pushed aside, according to health officials, raising doubts about the ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Helen Chu, MD, urged doctors to find "science-based recommendations" from the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American Academy of ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Meissner was previously listed in April as a consultant to the RSV vaccines work group for the CDC committee, before Kennedy ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

After firing the former members of ACIP earlier this week, Kennedy has appointed eight new members to the vaccine advisory board – including some vaccine skeptics.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued ...